Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) Patents (Class 514/34)
  • FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
    Publication number: 20120244110
    Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 27, 2012
    Applicant: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Jason Duquette, Michael W. Gribble, JR., Justin N. Huard, Kathleen S. Keegan, Zhihong Li, Sarah E. Lively, Lawrence R. McGee, Mark L. Ragains, Xianghong Wang, Margaret F. Weidner, Jian Zhang
  • METHODS FOR TREATING MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH PROTEASOME INHIBITOR
    Publication number: 20120244214
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: June 5, 2012
    Publication date: September 27, 2012
    Inventor: Jerome B. Zeldis
  • Combination treatment for bladder cancer
    Patent number: 8273721
    Abstract: Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and trospium chloride.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: September 25, 2012
    Assignee: Endo Pharmaceuticals Solutions Inc.
    Inventor: James E. Shipley
  • METHOD FOR TREATING BREAST CANCER AND OVARIAN CANCER
    Publication number: 20120237502
    Abstract: The present invention relates to a method for the prevention or treatment of certain breast cancers or ovarian cancer comprising administering to a patient in need thereof of a therapeutically effective amount of a 17,20-lyase inhibitor, wherein the breast cancer or ovarian cancer is estrogen receptor (ER) negative.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 20, 2012
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: James W. Darnowski
  • DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER
    Publication number: 20120238518
    Abstract: Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 20, 2012
    Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human Services
    Inventors: Anna E. Maciag, Larry K. Keefer, Joseph E. Saavedra, Lucy M. Anderson, Harinath Chakrapani
  • COMPOUNDS AND METHODS FOR TREATING NEOPLASIA
    Publication number: 20120238488
    Abstract: The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
    Type: Application
    Filed: June 22, 2010
    Publication date: September 20, 2012
    Inventors: Konstantinos Alevizopoulos, Theodora Calogeropoulou, Christos Stournaras
  • FUSED AMINO PYRIDINE AS HSP90 INHIBITORS
    Publication number: 20120237508
    Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
    Type: Application
    Filed: March 20, 2012
    Publication date: September 20, 2012
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Combinations and modes of administration of therapeutic agents and combination therapy
    Patent number: 8268348
    Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: September 18, 2012
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Salinosporamides and Methods for Use Thereof
    Publication number: 20120230972
    Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
  • METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE
    Publication number: 20120230983
    Abstract: Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Inventors: George W. Muller, Peter H. Schafer, Hon-Wah Man, Ling-Hua Zhang, Anita Gandhi, Rajesh Chopra
  • CROSSLINKING BRANCHED MOLECULE THROUGH THIOL-DISULFIDE EXCHANGE TO FORM HYDROGEL
    Publication number: 20120232027
    Abstract: In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the solution is adjusted to initiate thiol-disulfide exchange in the precursor, thus crosslinking the precursor through disulfide bonds formed by thiol-disulfide exchange. After the precursor is sufficiently crosslinked to form a hydrogel, the pH in the solution is adjusted to inhibit further thiol-disulfide exchange in the hydrogel. Further, a hydrogel matrix may comprise a polymer substantially crosslinked through disulfide bonds. The polymer may comprise a hydrophobic poly(amido amine) core and an amino-functionalized hydrophilic shell.
    Type: Application
    Filed: November 24, 2009
    Publication date: September 13, 2012
    Applicant: Agency for Science Technology and Research
    Inventors: Decheng Wu, Ye Liu, Chee Leng Lay
  • MOLECULAR BIOMARKER SET FOR EARLY DETECTION OF OVARIAN CANCER
    Publication number: 20120231090
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Inventors: Vladimir Bajic, Mandeep Kaur
  • Treatment of hyperproliferative conditions of body surfaces
    Patent number: 8263567
    Abstract: The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis. In particular the invention relates to treatment of psoriasis, and preferably to treatment of psoriasis with valrubicin topically applied.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: September 11, 2012
    Assignee: Valderm APS
    Inventors: Bjarne Bymose, Thomas Broe Christensen
  • METHOD FOR CARRYING THERAPEUTIC SUBSTANCES INTO CELLS
    Publication number: 20120225128
    Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Inventors: Andreas JORDAN, Norbert Waldoefner, Regina Scholz
  • TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20120225061
    Abstract: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 1, 2012
    Publication date: September 6, 2012
    Inventors: Matthew Burger, Yu Ding, Wooseok Han, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
  • Methods and Compositions for Improved Deliver, Expression or Activity of RNA Interference Agents
    Publication number: 20120225115
    Abstract: The present disclosure provides methods and compositions for enhanced delivery of siRNA or miRNA, into the interior of multilayered tissues, and into the cytoplasm or nucleus of cells of a tissue. Such methods and compositions yield tumor-selective and intracellular delivery of RNAi agents and allow for RNAi-mediated activity such as knock-down of the target genes and associated products. The current disclosure further provides methods and compositions for improving the intracellular bioavailability of nucleotide agents.
    Type: Application
    Filed: April 11, 2012
    Publication date: September 6, 2012
    Inventors: Jessie L.-S. Au, M. Guillaume Wientjes, Ze Lu, Jie Wang
  • MIXED MICELLES
    Publication number: 20120225017
    Abstract: This disclosure is directed to mixed micelle compositions for administration of e.g., therapeutic agents or imaging agents to a subject.
    Type: Application
    Filed: February 23, 2012
    Publication date: September 6, 2012
    Applicants: University of Washington through its Center for Commercialization, OMEROS CORPORATION
    Inventors: Wayne R. Gombotz, Suzie Pun, Christopher Mount, Tae Hee Kim, Benjamin W. Dulken
  • POLYMER CONJUGATED PROTEIN MICELLES
    Publication number: 20120219600
    Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Inventors: Omathanu P. Perumal, Satheesh K. Podaralla, Ranjith Kumar Averineni
  • SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE
    Publication number: 20120219522
    Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 30, 2012
    Inventor: Ning XI
  • Therapeutic Use of a TLR Agonist and Combination Therapy
    Publication number: 20120219615
    Abstract: The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.
    Type: Application
    Filed: October 3, 2011
    Publication date: August 30, 2012
    Applicants: The Trustees of the University of Pennsylvania, VentiRx Pharmaceuticals, Inc.
    Inventors: Robert Hershberg, George Coukos, Gregory Dietsch, Andrea Facciabene, Kristi Manjarrez, Tressa D. Randall
  • TYROSINE KINASE RECEPTOR ANTAGONISTS AND METHODS OF TREATMENT FOR PANCREATIC CANCER
    Publication number: 20120214758
    Abstract: A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: The Regents of the University of California
    Inventors: Ira GOLDFINE, John Kerner, Betty A. Maddux, Michael Campbell, Jack F. Youngren, Peter Kushner
  • MICROSPHERES FOR ACTIVE EMBOLIZATION
    Publication number: 20120213831
    Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.
    Type: Application
    Filed: May 2, 2012
    Publication date: August 23, 2012
    Applicant: BIOSPHERE MEDICAL, INC.
    Inventors: Jean-Marie Vogel, Egisto Boschetti
  • Methods and Compositions for Treating Cancer Using Proteasome Inhibitors
    Publication number: 20120214757
    Abstract: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent.
    Type: Application
    Filed: September 23, 2011
    Publication date: August 23, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Teru Hideshima, Constantine S. Mitsiades, Nicholas Mitsiades
  • 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS
    Publication number: 20120213791
    Abstract: The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof, and combinations thereof with other anti-cancer agents, for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 23, 2012
    Applicant: ASTEX THERAPEUTICS, LTD.
    Inventors: Valerio BERDINI, Michael Alistair O'BRIEN, Maria Grazia CARR, Theresa Rachel EARLY, Adrian Liam GILL, Gary TREWARTHA, Alison Jo-Anne WOOLFORD, Andrew James WOODHEAD, Paul Graham WYATT
  • HYBRID NANOMATERIALS CONSISTING OF PSEUDOROTAXANES, PSEUDOPOLYROTAXANES, ROTAXANES, POLYROTAXANES, NANOPARTICLES AND QUANTUM DOTS
    Publication number: 20120208780
    Abstract: This invention provides the synthesis of biocompatible and high functional hybrid nanomaterials consisting of pseudorotaxanes, pseudopolyrotaxanes, rotaxanes, polyrotaxanes, nanoparticles and quantum dots (QDs). The molecular self-assembly of hybrid nanomaterials lead to the formation of nano-objects with different shapes such as core-shell, spindle-like or necklaces. Due to their well-defined molecular self-assemblies, carbohydrate backbone, high functionality and several types of functional groups together with the high luminescence yield, thermal and physical properties and synthesized hybrid nanostructures were recognized as promising candidates for a wide range of applications.
    Type: Application
    Filed: February 16, 2011
    Publication date: August 16, 2012
    Applicant: LORESTAN UNIVERSITY
    Inventors: Mohsen Adeli, Mahdieh Kalantari, Maasoomeh Sagvand
  • Imidazoquinolines as lipid kinase inhibitors
    Publication number: 20120207751
    Abstract: The invention relates to a combination comprising compounds of formula (I) and one or more other antiproliferative compounds, hormones or radiation, pharmaceutical preparations comprising the combination thereof, and the application thereof in a process for the treatment of tumors.
    Type: Application
    Filed: April 23, 2012
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Frédéric Stauffer, Pascal Furet
  • PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
    Publication number: 20120207763
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.
    Type: Application
    Filed: April 20, 2012
    Publication date: August 16, 2012
    Applicants: ASTEX THERAPEUTICS LIMITED, NOVARTIS AG
    Inventors: Christopher Thomas BRAIN, Moo Je SUNG, Gebhard THOMA
  • MSH3 Expression Status Determines the Responsiveness of Cancer Cells to the Chemotherapeutic Treatment with PARP Inhibitors and Platinum Drugs
    Publication number: 20120207856
    Abstract: Methods for treating a patient at risk for or diagnosed with colorectal cancer are disclosed herein. The method of the present invention determines the overall expression of MSH3 in cells suspected of being colorectal cancer cells from the patient and predicting the efficacy of therapy with a genotoxic anti-neoplastic agent for treating the patient, wherein a decrease in the overall expression of MSH3 in the patient cells when compared to the expression of MSH3 in normal colorectal cells indicates a predisposition to responsiveness to genotoxic anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the genotoxic anti-neoplastic agent therapy to patients.
    Type: Application
    Filed: February 10, 2012
    Publication date: August 16, 2012
    Applicant: Baylor Research Institute
    Inventors: Ajay Goel, C. Richard Boland, Minoru Koi, Masanobu Takahashi
  • System and Method for Diagnosis and Treatment
    Publication number: 20120201747
    Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 9, 2012
    Applicant: POP TEST CORTISOL LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
    Publication number: 20120202760
    Abstract: This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 9, 2012
    Inventor: Rashida A. Karmali
  • Compositions and methods of improving the tolerability of daunorubicin when given as orotate salt
    Publication number: 20120202761
    Abstract: This invention is in the field of anthracycline family of drugs. More particularly, it concerns converting daunorubicin hydrochloride to an orotate salt and providing methods of improving the tolerability of daunorubicin in animals by reducing the adverse effects and toxicity in noncancerous tissues. Daunorubicin orotate provides a safer treatment for specific types of leukemias and neuroblastomas in adults and in pediatric patients.
    Type: Application
    Filed: February 27, 2012
    Publication date: August 9, 2012
    Applicant: Savvipharm Inc
    Inventor: Rashida A. Karmali
  • Prodrugs cleavable by CD26
    Patent number: 8236756
    Abstract: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: August 7, 2012
    Assignees: Consejo Superior de Investigaciones Clentificas (CSIC), K.U. Leuven Research & Development
    Inventors: Jan Balzarini, Maria José Camarasa Ríus, Sonsoles Velázquez Díaz
  • OLIGONUCLEOTIDES INHIBITING CELLULAR MIGRATION
    Publication number: 20120195890
    Abstract: Oligonucleotides inhibiting cellular migration, and the use of at least one inhibitor of protein expression, which inhibits the expression of TSP1 protein, or a protein, which controls the expression of TSP1 or mediates the activity of TSP1, or one inhibitor of protein activity, this inhibitor inhibiting the activity of the TSP1 protein, in particular the activity responsible for the stimulation of cell migration, or one protein which controls the expression or mediates the activity of TSP1 for the manufacture of a drug for the prevention or the treatment of primary tumors or invasive or metastatic tumors.
    Type: Application
    Filed: July 30, 2010
    Publication date: August 2, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florence Cabon, Virginie Firlej, Catherine Gallou-Kabani, Natalia Catherine Prevarskaya
  • PROCESS FOR PRODUCING AN INJECTABLE MEDICAMENT PREPARATION
    Publication number: 20120195832
    Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
    Type: Application
    Filed: March 7, 2012
    Publication date: August 2, 2012
    Applicant: KTB Tumorforschungs GMBH
    Inventor: Felix Kratz
  • Treatment of lung cancer
    Patent number: 8232253
    Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: July 31, 2012
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
  • SELECTIVE OXIDATION OF C-H BONDS OF MODIFIED SUBSTRATES BY P450 MONOOXYGENASE
    Publication number: 20120190635
    Abstract: The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.
    Type: Application
    Filed: September 27, 2010
    Publication date: July 26, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shengying Li, David H. Sherman, John Montgomery, Mani R. Chaulagain, Allison R. Knauff
  • CYCLIZED DERIVATIVES AS EG-5 INHIBITORS
    Publication number: 20120189623
    Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:
    Type: Application
    Filed: April 3, 2012
    Publication date: July 26, 2012
    Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
  • MONOMERS AND PHASE-SEPARATED BIOCOMPATIBLE POLYMER COMPOSITIONS PREPARED THEREFROM FOR MEDICAL USES
    Publication number: 20120189713
    Abstract: The invention relates to novel monomers of Formula (I) useful for preparation of phase-separated biocompatible polymers or polymer compositions. These polymers or polymer compositions may be bioresorbable and/or biodegradable and have desirable mechanical properties, such as fracture and/or fatigue toughness, which have not been a primary design criteria for such polymers previously. The polymers or polymer compositions are useful in a variety of medical applications, such as in the fabrication of medical devices. Therefore, methods for preparing these polymers or polymer compositions and medical devices are also encompassed by this disclosure.
    Type: Application
    Filed: July 31, 2010
    Publication date: July 26, 2012
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joachim B. Kohn, Durgadas Bolikal, Ramiro Rojas
  • Injectable, injection solution, and injection kit preparation
    Patent number: 8227430
    Abstract: Provided is an injectable comprising: an anthracycline antineoplastic antibiotic; and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: July 24, 2012
    Assignee: Meiji Seika Pharma Co., Ltd
    Inventors: Teruhisa Yoshizawa, Akiko Miyoshi, Masato Ota
  • STEVIA EXTRACT OR STEVIOL FOR HAIR CARE
    Publication number: 20120184500
    Abstract: This invention relates to the use of an oral composition comprising Stevia extract, steviol precursors, or steviol which enhances the appearance of hair. It further relates methods of improving the appearance of hair by oral administration of an effective amount of Stevia extract, steviol precursors or steviol.
    Type: Application
    Filed: July 20, 2010
    Publication date: July 19, 2012
    Inventors: Regina Goralczyk, Annis Olivia Mayne-Mechan, Jenny Piussi, Henry Rieger, Hasan Mohajeri
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20120183535
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 19, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20120183537
    Abstract: According to the invention there is provided a compound of formula (I) wherein: A represents C(?N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(?N—W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(—NH—W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRxRy]n—; W represents —[CRxRy]m— or —C(O)—[CRxRy]p—; Q represents a bond, —N(Ra)—, —S—, or —O—; A1 to A5 respectively represent C(R1), C(R2), C(R3), C(R4) and C(R5), or, alternatively, up to two of A1 to A5 may independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more R6 groups, which compounds are useful in the treatment of cancer.
    Type: Application
    Filed: July 8, 2010
    Publication date: July 19, 2012
    Inventors: Jacob Westman, Allan Hallett, Jan Vagberg
  • SPARC ANTISENSE COMPOSITIONS AND USES THEREOF
    Publication number: 20120183538
    Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 19, 2012
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Vuong Trieu, Larn Hwang, Neil Desai
  • DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS
    Publication number: 20120177634
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Application
    Filed: February 22, 2012
    Publication date: July 12, 2012
    Inventor: Lee Roy Morgan
  • MEDICAL USE OF SPLA2 HYDROLYSABLE LIPOSOMES
    Publication number: 20120177726
    Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.
    Type: Application
    Filed: September 16, 2010
    Publication date: July 12, 2012
    Applicant: Bio-Bedst ApS
    Inventors: Morten Just Petersen, Fredrik Melander, Andres Falk Vikbjerg, Sune Allan Petersonm, Mognes Winkel Madsen
  • Preparation Method of Drug Loaded Emulsion
    Publication number: 20120177699
    Abstract: A preparation method of drug loaded emulsion is disclosed. The method comprises the steps of: preparing a non-self emulsifying O/W blank emulsion having no active ingredients; then, adding therapeutically effective amount of active ingredients to the 0/W blank emulsion, adjusting pH to distribute the active ingredients through the membrane to obtain the desired emulsion.
    Type: Application
    Filed: June 3, 2010
    Publication date: July 12, 2012
    Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Xinyong Tong, Haifeng Wang, Li Lu, Liang Chen, Yuan Shi
  • Stabilized Aptamers To Platelet Derived Growth Factor And Their Use As Oncology Therapeutics
    Publication number: 20120171304
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: September 16, 2011
    Publication date: July 5, 2012
    Inventors: Dilara Grate, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Response Prediction in Cancer Treatment Involving p53 Adapted Cancer Therapy
    Publication number: 20120171305
    Abstract: Methods for predicting negative consequences of a treatment of a patient with a therapy comprising determining the genetic status of the patient's tumor with respect to p53 by determining in a sample of body fluid or a tissue sample of the patient containing tumor cells or cell-free tumor DNA whether the whole p53 gene is present in native form or whether the p53 gene has one or more mutations. In further embodiments the patient is predicted to be a patient who will suffer negative consequences of a therapy interfering with the cell cycle if the whole p53 gene is present in native form and a patient who will suffer negative consequences of a therapy inducing p53 dependent apoptosis if the p53 gene has one or more mutations. Methods of treatment are also contemplated.
    Type: Application
    Filed: January 5, 2012
    Publication date: July 5, 2012
    Inventor: Daniela Kandioler
  • METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE
    Publication number: 20120172292
    Abstract: This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Ivan Gusarov
  • NANO-SIZED PARTICLES COMPRISING MULTI-HEADED AMPHIPHILES FOR TARGETED DRUG DELIVERY
    Publication number: 20120164072
    Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.
    Type: Application
    Filed: May 4, 2010
    Publication date: June 28, 2012
    Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman